iRadimed Corporation
78.31-1.48 (-1.85%)
Oct 29, 4:00:02 PM EDT · NasdaqGM · IRMD · USD
Key Stats
Market Cap
996.10MP/E (TTM)
48.64Basic EPS (TTM)
1.61Dividend Yield
0.01%Recent Filings
8-K
Board transition at Iradimed
Iradimed Corporation announced a board transition on August 27, 2025, when director Anthony Vuoto retired for personal reasons, effective immediately, after nine years of service. The board swiftly appointed Joe Kiani, Masimo founder and medical tech innovator, as his replacement on September 2, 2025, maintaining the five-member size while adding his audit and compensation committee expertise. Kiani's deep industry knowledge bolsters strategic guidance. No disagreements prompted Vuoto's exit.
8-K
Record Q2 revenue, raised guidance
Iradimed posted record Q2 2025 revenue of $20.4 million, up 14% from last year, with GAAP diluted EPS climbing 18% to $0.45 amid a steady 78% gross margin. The company raised full-year guidance to $80.0-$82.5 million in revenue and $1.60-$1.70 GAAP EPS, signaling robust demand for its MRI-compatible devices. It declared a $0.17 quarterly dividend, payable August 28. Yet facility move risks Q3 inefficiencies.
10-Q
Q2 FY2025 results
IRADIMED's Q2 revenue climbed 14% year-over-year to $20.4 million, fueled by strong U.S. demand for IV infusion pumps and disposables, while international sales dipped 8%. Gross margins held steady at 78%, and operating income rose 21% to $6.8 million, lifting diluted EPS to $0.45 from $0.38. Cash from operations hit $12.0 million year-to-date, up from $10.5 million, supporting $6.7 million in capex for a new facility; free cash flow stood at $5.3 million (derived). No debt weighs on the balance sheet, with $53.0 million in cash. The new facility bolsters growth capacity. Yet regulatory hurdles could snag product rollouts.
8-K
Annual meeting results
Iradimed Corporation's stockholders, at the June 19, 2025 annual meeting, elected Roger Susi, Monty Allen, Anthony Vuoto, Hilda Scharen-Guivel, and James Hawkins to the board, with votes ranging from 8.4 million to 10.8 million for each. They ratified RSM US LLP as auditors for the fiscal year ending December 31, 2025, with 11.8 million votes in favor. An advisory vote approved executive compensation, passing 10.8 million to 287,000. Strong support signals investor confidence in governance.
8-K
FDA clears MRidium 3870 pump
iRadimed Corporation secured FDA 510(k) clearance for its next-generation MRidium 3870 IV Infusion Pump on May 29, 2025, bolstering its sole position as the world's only non-magnetic MRI infusion pump provider. This advanced system features an ultrasonic motor, non-interfering RF emissions, and a touchscreen interface for safer fluid delivery in high-field environments. Rollout starts with select deployments in Q4 2025, ramping in 2026. Yet regulatory delays persist as a risk.
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
CNMD
CONMED Corporation
46.71-0.61
INMD
InMode Ltd.
14.92-0.35
IRIX
IRIDEX Corporation
1.03+0.02
IRME
IR-Med Inc.
0.03+0.00
ITGR
Integer Holdings Corporation
65.30-2.70
MASI
Masimo Corporation
142.91-3.50
MDT
Medtronic plc.
91.73-1.50
RMD
ResMed Inc.
253.62-2.95
VMD
Viemed Healthcare, Inc.
6.54-0.32